What is Bexson Biomedical?
Bexson Biomedical, Inc. is a research-stage company focused on developing a novel ketamine-based combination product treatment platform. Established in 2017 and headquartered in Santa Barbara, California, the company aims to address a wide variety of pain management and mental health disorders through its innovative therapeutic approach. The company's current lifecycle stage, indicated by its major enterprise-level funding, suggests a transition from early-stage research towards clinical validation and market preparation.
How much funding has Bexson Biomedical raised?
Bexson Biomedical has raised a total of $4.8M across 1 funding round:
Series A
$4.8M
Series A (2021): $4.8M with participation from Noetic Psychedelic Fund
Key Investors in Bexson Biomedical
Noetic Psychedelic Fund
Noetic Psychedelic Fund is an investment firm that focuses on the burgeoning psychedelic medicine sector, likely providing strategic capital and expertise to companies advancing novel therapies for mental health and neurological conditions.
What's next for Bexson Biomedical?
With its recent major strategic investment, Bexson Biomedical is poised for accelerated growth and the advancement of its ketamine-based treatment platform. The company is expected to leverage this capital infusion to further its research and development initiatives, potentially moving towards clinical trials and regulatory submissions. This strategic financing will likely enable Bexson Biomedical to solidify its position in the competitive landscape of pain management and mental health therapeutics, paving the way for future commercialization and broader patient access.
See full Bexson Biomedical company page
